[Especially in patients with diabetes, onychomycosis is not a harmless illness].
D000284:Administration, Oral; D000287:Administration, Topical; D000935:Antifungal Agents / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004886:Erysipelas / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D009281:Naphthalenes / Q000008:administration & dosage*; D014009:Onychomycosis / Q000150:complications* / Q000188:drug therapy*; D012307:Risk Factors; D055502:Secondary Prevention; D018805:Sepsis / Q000209:etiology* / Q000517:prevention & control; D015163:Superinfection / Q000209:etiology* / Q000517:prevention & control; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine